Reading Time: 5 minutes A recent study has assessed the extent to which genetics plays a role in the development of MND, in both familial and non-familial (sporadic) forms of the disease. This research has arisen as a result of an international collaboration of several research institutes, many of whom have been supported by the MND Association. The world-class…
Reading Time: 4 minutes A research paper published recently has investigated the effect of a compound called ‘NU-9’ in mice models of MND. Before we go on, it is important to define ‘compound’ in this context. A compound is something that has pharmacological or biological activity that is likely to be therapeutically useful. It serves as a starting point…
Reading Time: 9 minutes A paper arising from research carried out at the University of Sheffield as part of the AMBRoSIA biobank, and in collaboration with the international Project MinE gene-hunting consortium, was recently published in the Journal of Neurology, Neurosurgery and Psychiatry. Researchers propose that a test for the most common MND genes could be offered to all…
Reading Time: 3 minutes A study conducted by researchers at the Euan MacDonald Centre at the University of Edinburgh has shed light on how improving the function of mitochondria – the power supply of nerve cells – could be a potential treatment for motor neurone disease, paper published this week in the journal, Acta Neuropathologica (2021). This study paves…
Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials Co-presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General…
Reading Time: 4 minutes It’s that time of year again. With just a week to go until the 31st International Symposium on ALS/MND, we thought we’d bring you an update on everything we’ve been doing to make sure we can still present the biggest scientific conference on ALS/MND in the world. Obviously, this year, things are looking a little…
Reading Time: 3 minutes A centaur was a creature from Greek mythology which was half-man and half-horse. Despite such an unusual appearance such a combination could have its advantages. It seems that another combination may hold promise in the future for people with ALS/MND (see our previous blog). The CENTAUR clinical trial, which tested a combination of two compounds,…
Reading Time: 2 minutes This week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried out across multiple North American clinics. The paper was published in the New England Journal of Medicine.
Reading Time: 3 minutes A recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug extends survival in people with the disease for much longer than was proposed in the original clinical trials.
Reading Time: 4 minutes Guest researcher blog post: My name is Sophie Nyberg and I am a neuroscientist currently working in the Lighthouse COVID-19 testing labs in Alderley Park, Cheshire, England.
